Table 4. Dose-effect EC75 values of drugs alone or in combinations in THP89GFP cells.
| Individual Drug | Double combination |
Triple combination |
||||||
|---|---|---|---|---|---|---|---|---|
| BRY:PNB (2.5:2) | BRY:PNB (5:2) | PNB:RMD (2:1) | BRY:RMD (2.5:1) | BRY:RMD (5:1) | BRY:PNB:RMD (2.5:2:1) | (5:2:1) | ||
| BRY (nM) | 31.4 ± 9.8 | 21.1 ± 3.78* | 26.67 ± 10.32 | 15.49 ± 3.96** | 21.31 ± 3.49 | 37.18 ± 17.21 | 20.68 ± 3.95* | |
| PNB (nM) | 28.87 ± 10.41 | 16.88 ± 3.03* | 10.67 ± 4.13*** | 23.81 ± 7.98 | 29.74 ± 13.75 | 8.27 ± 1.58*** | ||
| RMD (nM) | 19.07 ± 6.9 | 11.9 ± 3.99* | 6.2 ± 1.59** | 4.26 ± 0.7*** | 14.88 ± 6.89 | 4.14 ± 0.79*** | ||
The 75% effective reactivation concentration (EC75) values (nM ± SD) in latently infected THP89GFP cells of BRY, PNB, and RMD drugs alone and in combination at the indicated ratios 24 h post-treatment are shown. Data are represented as the mean ± SD of at least three independent experiments. Statistics were performed between the calculated EC75 values of the drug at single and combined treatments. ***p < 0.001; **p < 0.005; *p < 0.05.